Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Colonis launches orange flavour gabapentin after 'palatability issues'

Colonis Pharma has launched epilepsy and neuropathic pain medicine gabapentin in an orange flavour.

The new flavour of Gabapentin Colonis 50mg/ml comes after “a number” of requests to manufacture an alternative to the original aniseed flavour, which has been available since 2012, Colonis said.

The manufacturer launched the orange flavour “to address palatability issues” children had experienced “arising from the aniseed” version.

The orange flavour "gives customers greater choice" and is a "straightforward alternative for pharmacists", Colonis continued.

Gabapentin can be used as an adjunctive therapy to treat epilepsy in adults and children aged six and above; or as a monotherapy in patients over 12, Colonis said.

It can also treat peripheral neuropathic pain – such as painful diabetic neuropathy and post-herpetic neuralgia – in adults, it added.

For more information, contact 01256 316 525

How often did you dispense Gabapentin?

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD008936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel